OUR LEADERSHIP

SIZHEN WANG

CO-FOUNDER ， CHAIRMAN AND CHIEF EXECUTIVE OFFICER
HAI YAN

CO-FOUNDER & CHIEF SCIENTIFIC OFFICER

YUNFU HU

CHIEF MEDICAL OFFICER
YUCHEN JIAO

CHIEF TECHNOLOGY OFFICER
VICTORIA LEI

CHIEF OPERATING OFFICER

TODD LIANG

CHIEF HUMAN RESOURCES OFFICER
EVAN XU

CHIEF FINANCIAL OFFICER
ZHAOHUI YIN

VICE PRESIDENT

CATHY ZHANG

VICE PRESIDENT

*The list is sorted alphabetically by last name

With extensive entrepreneurial experience across multiple disciplines and corporate management capabilities, Sizhen Wang leads Genetron Health in consistently exploring cancer genomics and promoting bio-innovative technology applications, in order to further the development of human health.

Sizhen Wang

Co-founder ， Chairman And Chief Executive Officer

Sizhen co-founded Genetron Health in 2013, which at present has become a leading precision oncology platform company in China. It was listed on Nasdaq (GTH) in June 2020 and became the largest precision oncology IPO in the world at that time. With the service portfolio of "cancer early screening + cancer diagnosis and monitoring + biopharma services", Genetron Health has served the top hospitals and physical examination institutions, dozens of pharmaceutical enterprises and scientific research institutions in China, and participated in a number of government livelihood projects and social welfare projects.In 2021, under Sizhen’s leadership, Genetron Health’s early precision lung cancer diagnosis and treatment project, a joint initiative with the West China Hospital of Sichuan University, won the second prize of China’s National Science and Technology Progress Award.

In 2004, Sizhen co-founded iTalkBB, a company providing global telephone, TV, data and mobile communication services to millions of users around the world. iTalkBB is now the leading Internet communications brand among Chinese communities in North America and Australia.

Sizhen also has ten years of experience working in the finance industry, including at Capital One and GD Capital.

Sizhen graduated from the HEC Paris School of Management with an MBA degree.

Evan Xu spent more than 12 years in international investment banks, with extensive experience in corporate finance and M&A. He previously held the sponsor principal license granted by Securities and Futures Commission, Hong Kong.

Evan Xu

Chief Financial Officer

Evan helped Genetron Health successfully listed in Nasdaq, as the largest IPO of precision oncology globally by then.

Evan previously served as a Director of Investment Banking Division at Deutsche Bank AG, Hong Kong.

Evan served as Executive Director of the Investment Banking Division at Goldman Sachs (Asia) L.L.C in Hong Kong.

Evan served as an analyst and associate at Lehman Brothers and Nomura Securities in Hong Kong.

Evan obtained a Master's degree from the National University of Singapore.

During her career, Victoria Lei has contributed to the success of several Fortune 500 companies, earning awards for her excellent management skills. Additionally, Victoria is a successful entrepreneur with extensive management experience spanning more than 20 years throughout North America, Australia and Asia.

Victoria Lei

CHIEF OPERATING OFFICER

Victoria is a visionary global business leader who is adept at formulating and executing innovative business strategies. She has consistently demonstrated strong leadership skills and market expansion capabilities.

Victoria has comprehensive experience in bringing high-tech products from concept to market. Her leadership experience encompasses the entire process of guiding new products from concept design, achieving scale and operational standardization, to implementation and market promotion.

Victoria holds a bachelor’s degree in management from the University of South Carolina and the Hotel Institute Montreux, Switzerland. She successfully completed the General Management Program of the Harvard Business School.

Cathy Zhang has profound experience in overseas business development and team management. She has worked for multinational companies (Fortune 500 companies) for over three decades.

Cathy Zhang

Vice President

Cathy previously worked as the director of sales and government affairs, as well as vice president of overseas markets at Alcatel.

Cathy previously led the overseas business development at Alcatel-Lucent Shanghai Bell.

Cathy previously worked for HP China and Ericsson.

Cathy graduated from Fudan University School of Management, and obtained her International MBA from University of Hong Kong.

Lin Teng has over two decades of experience working in the pharmaceutical industry, includes over 15 years of management experience with oncology companies.

Lin Teng

Vice President

Lin is experienced in team management and resource integration. Her strong leadership lead the business team rapidly develop and gain more market share in the tumor molecular diagnosis sector. She also has in-depth and unique insights into all aspects of the tumor ecological chain, including diagnosis and treatment.

Lin has served at Roche and Eli-Lilly China.

Lin obtained an EMBA from China Europe International Business School (CEIBS), and a bachelor’s degree in Medicine from Shandong University.

Zhaohui Yin has over 25 years of experience in commerce, sales and management in health care, all of which rank among the top 10 pharmaceutical enterprises globally. He has extensive experience in the fields of IVD, gene sequencing and related equipment or high-value supplements, particularly in building a comprehensive dealer system from scratch, with successful experience in graded sales management.

Zhaohui Yin

Vice President

Zhaohui previously served as Deputy General Manager of Guangzhou Darui Biotechnology Co. Ltd. Under his leadership, Guangzhou Darui Biotechnology Co. Ltd. became a leading enterprise focused on reproductive health in the field of genetic testing. He founded the overseas testing company Ruikang International and served as General Manager, establishing the company’s operating team and doubling its revenue.

Zhaohui previously served as the business and sales director at Becton, Dickinson and Company, as well as Abbott.

Zhaohui has held sales and management positions at Johnson & Johnson and GSK.

Zhaohui is a licensed anesthesiologist.

Zhaohui obtained bachelor degree of clinical medicine from the Southeast University, and was a visiting scholar at the School of Medicine, Stanford University.

Hai Yan had been a faculty member at Duke University School of Medicine, as the Henry S. Friedman Distinguished Professor of Neuro-Oncology, a Professor of Pathology, and a Professor of Pharmacology and Cancer Biology. He once served as the Director of Neuro Oncology Program at Duke Cancer Institute. He is a Linse Bock Visiting Professor of Neuro-Oncology at the Mayo Clinic, and an elected member of the American Society for Clinical Investigation (ASCI). He was recognized for his influential original discoveries and research in brain tumors. His research team and collaborators found that IDH1 and IDH2 were mutated in malignant gliomas; also discovered the major genetic basis for maintaining telomere length in cancers, including TERT promoter mutations for activating telomerase, and ATRX and Smarcal1 mutations underlying Alternative Lengthening of Telomeres in gliomas.

Hai Yan

Co-founder & Chief Scientific Officer

In 2021, he was awarded the International Prize for Translational Neuroscience from the Gertrud Reemtsma Foundation through the Max Planck Society in Germany, one of the most prominent awards in neuroscience.

He received The Bernard F. Fetter Teaching Scholar Award for outstanding teaching and servicing in the undergraduate medical education program at Duke University School of Medicine. He is a Duke School of Medicine Noteworthy Faculty Member. He previously was honored as a Damon Runyon Foundation Scholar, an American Cancer Society Scholar, a V Foundation Scholar, and a James S. McDonnell Scholar. Hai received the 2014 AACR Team Science Award for his pioneering discovering IDH1, IDH2 mutations in gliomas.

He holds multiple U.S. patents. He is one of the inventors of BEAMing technology, which has been clinically implemented for liquid biopsy of cancer.

He has published 126 scientific research papers in SCI series journals, including NEJM, Nature, and Science (32,500+ citations, h-index 65), as first or corresponding author.

He received his PhD in Molecular and Cellular Biology Program from Columbia University and post-doctoral training with Dr. Bert Vogelstein and Dr. Kenneth Kinzler at The Johns Hopkins University School of Medicine.

Yuchen Jiao studied the cancer genomics of various tumors, and identified novel tumor suppressor genes including ATRX, which were listed as an important diagnostic marker by the WHO classification of tumors of the central nervous system.

Yuchen Jiao

Chief Technology Officer

Yuchen published more than 20 research papers in Science, Nature Genetics, PNAS and other journals as first or corresponding author.

Yuchen finished his postdoctoral training in the team of Professor Bert Vogelstein.

Yuchen received his M.D. in clinical medicine from Peking Union Medical College and his Ph.D. degree in biological chemistry at the Johns Hopkins University.

Yunfu Hu has more than two decades of experience in regulatory and business management related to medical devices and pharmaceutical R&D industries.

Yunfu Hu

Chief Medical Officer

Under Yunfu’s leadership, Genetron Health’s blood-based next-generation sequencing (NGS) test, HCCscreen™️, received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), which made it the first product in China's molecular diagnostic industry to achieve this recognition.

Yunfu previously served as Deputy Director of the Division of Molecular Genetics and Pathology in the Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health at FDA. He was responsible for supervising in vitro diagnostic products such as cancer molecular diagnosis, companion diagnostic products, gene testing, artificial intelligence in pathology and cytological detection.

Some of Yunfu’s notable FDA approvals include: Myriad Genetics' BRAC Analysis CDx; Foundation Medicine's FoundationFocus CDxBRCA; ThermoFisher Oncomine Dx Target Test; FoundationOne CDx; Roche Cobas EGFR Mutation Test v2; Exact Sciences’ Cologuard and Epigenomics’ Epi ProColon.

Yunfu has 10 years of product development experience with world-class diagnostic and pharmaceutical companies. He has made outstanding achievements in precision medical research, tumor biomarker development and diagnostic product development and registration.

Yunfu obtained his Ph.D. in Veterinary Physiology & Pharmacology and Master’s degree in Reproductive Endocrinology at Ohio State University. He was Postdoctoral Fellow of Fox Chase Cancer Center.

Todd Liang has more than 20 years of management experience in HR development. He has worked as head of HR at multinational companies from Europe and the U.S., as well as at internet start-ups, and local holding companies in China. He has experience across various industries including fast-moving consumer goods, e-commerce, real-estate, hospitality and education.

Todd Liang

Chief Human Resources Officer

Todd has served as Chief Human Resources Officer of OneSmart Education Group; Vice President of Wanda Hotel Group; Human Resources Vice President of YHD.com; Human Resources Director of Asia Pacific Region of SSL Group; and Human Resources Manager of GE Plastics Greater China. Over the course of his career, Todd led HR teams to sufficiently support fast business growth by strengthening talent and organizational capabilities.

Todd obtained an EMBA from China Europe International Business School (CEIBS), and a B.A. from Southwest Jiaotong University.